{"id":"https://openalex.org/W2560127142","doi":"https://doi.org/10.1182/blood.v114.22.301.301","title":"A Phase 1/2 Multi-Center, Randomized, Open Label Dose Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of Pomalidomide Alone or in Combination with Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide and Bortezomib.","display_name":"A Phase 1/2 Multi-Center, Randomized, Open Label Dose Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of Pomalidomide Alone or in Combination with Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide and Bortezomib.","publication_year":2009,"publication_date":"2009-11-20","ids":{"openalex":"https://openalex.org/W2560127142","doi":"https://doi.org/10.1182/blood.v114.22.301.301","mag":"2560127142"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v114.22.301.301","doi":"https://doi.org/10.1182/blood.v114.22.301.301","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v114.22.301.301","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5043526996","display_name":"Paul Gerard Guy Richardson","orcid":"https://orcid.org/0000-0002-7426-8865","observed_orcids":["https://orcid.org/0000-0002-7426-8865"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Paul Richardson","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA, USA,","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023752321","display_name":"David Samuel DiCapua Siegel","orcid":"https://orcid.org/0000-0002-3604-2574","observed_orcids":["https://orcid.org/0000-0002-3604-2574"]},"institutions":[{"id":"https://openalex.org/I1324520350","display_name":"Hackensack University Medical Center","ror":"https://ror.org/008zj0x80","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1324520350"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David Siegel","raw_affiliation_strings":["Hackensack University Medical Center, Hackensack, NJ, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hackensack University Medical Center, Hackensack, NJ, USA,","institution_ids":["https://openalex.org/I1324520350"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077110117","display_name":"Rachid Baz","orcid":"https://orcid.org/0000-0003-4538-4733","observed_orcids":["https://orcid.org/0000-0003-4538-4733"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rachid Baz","raw_affiliation_strings":["H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA,","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086214161","display_name":"Susan L. Kelley","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2802474972","display_name":"Multiple Myeloma Research Foundation","ror":"https://ror.org/03ww1bx13","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I2802474972"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Susan L. Kelley","raw_affiliation_strings":["Multiple Myeloma Research Consortium, Norwalk, CT,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Multiple Myeloma Research Consortium, Norwalk, CT,","institution_ids":["https://openalex.org/I2802474972"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045740077","display_name":"Nikhil C. Munshi","orcid":"https://orcid.org/0000-0002-7344-9795","observed_orcids":["https://orcid.org/0000-0002-7344-9795","https://orcid.org/0000-0002-8397-100X"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nikhil C. Munshi","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA, USA,","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102841436","display_name":"Daniel M. Sullivan","orcid":"https://orcid.org/0009-0003-0951-9781","observed_orcids":["https://orcid.org/0009-0003-0951-9781","https://orcid.org/0000-0002-2183-1773"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Daniel Sullivan","raw_affiliation_strings":["H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA,","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111763486","display_name":"Laura McBride","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1324520350","display_name":"Hackensack University Medical Center","ror":"https://ror.org/008zj0x80","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1324520350"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Laura McBride","raw_affiliation_strings":["Hackensack University Medical Center, Hackensack, NJ,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hackensack University Medical Center, Hackensack, NJ,","institution_ids":["https://openalex.org/I1324520350"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051627358","display_name":"Deborah S. Doss","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Deborah Doss","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA, USA,","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028521293","display_name":"Gail Larkins","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387155837","display_name":"Celgene (United States)","ror":"https://ror.org/0527yg379","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4387155837"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Gail Larkins","raw_affiliation_strings":["Celgene Corporation, Summit, NJ,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celgene Corporation, Summit, NJ,","institution_ids":["https://openalex.org/I4387155837"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113791692","display_name":"Christian J. Jacques","orcid":"https://orcid.org/0009-0006-9717-3814","observed_orcids":["https://orcid.org/0009-0006-9717-3814"]},"institutions":[{"id":"https://openalex.org/I4387155837","display_name":"Celgene (United States)","ror":"https://ror.org/0527yg379","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4387155837"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Christian Jacques","raw_affiliation_strings":["Celgene Corporation, Summit, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celgene Corporation, Summit, NJ, USA","institution_ids":["https://openalex.org/I4387155837"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Arlene Donaldson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387155837","display_name":"Celgene (United States)","ror":"https://ror.org/0527yg379","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4387155837"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Arlene Donaldson","raw_affiliation_strings":["Celgene Corporation, Summit, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celgene Corporation, Summit, NJ, USA","institution_ids":["https://openalex.org/I4387155837"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5032464400","display_name":"Kenneth Carl Anderson","orcid":"https://orcid.org/0000-0002-6418-0886","observed_orcids":["https://orcid.org/0000-0002-6418-0886"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kenneth C. Anderson","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA, USA,","institution_ids":["https://openalex.org/I4210117453"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":5,"corresponding_author_ids":["https://openalex.org/A5028521293","https://openalex.org/A5051627358","https://openalex.org/A5111763486","https://openalex.org/A5113791692"],"corresponding_institution_ids":["https://openalex.org/I1324520350","https://openalex.org/I4210117453","https://openalex.org/I4387155837"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":5.4786,"has_fulltext":false,"cited_by_count":39,"citation_normalized_percentile":{"value":0.96175551,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":89,"max":99},"biblio":{"volume":"114","issue":"22","first_page":"301","last_page":"301"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11221","display_name":"Bone health and treatments","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12534","display_name":"Protein Degradation and Inhibitors","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pomalidomide","display_name":"pomalidomide","score":0.9980000257492065},{"id":"https://openalex.org/keywords/dexamethasone","display_name":"dexamethasone","score":0.9309999942779541},{"id":"https://openalex.org/keywords/relapsed-refractory-multiple-myeloma","display_name":"relapsed/refractory multiple myeloma","score":0.9279999732971191},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.8730000257492065},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.8090000152587891},{"id":"https://openalex.org/keywords/lenalidomide-refractory-disease","display_name":"lenalidomide-refractory disease","score":0.8090000152587891},{"id":"https://openalex.org/keywords/bortezomib-refractory-disease","display_name":"bortezomib-refractory disease","score":0.9789999723434448},{"id":"https://openalex.org/keywords/venous-thromboembolism","display_name":"venous thromboembolism","score":0.7020000219345093},{"id":"https://openalex.org/keywords/thrombocytopenia","display_name":"thrombocytopenia","score":0.6320000290870667},{"id":"https://openalex.org/keywords/neutropenia","display_name":"neutropenia","score":0.4650000035762787},{"id":"https://openalex.org/keywords/treatment-related-adverse-events","display_name":"treatment-related adverse events","score":0.38100001215934753},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.4390000104904175},{"id":"https://openalex.org/keywords/immunomodulators","display_name":"immunomodulators","score":0.3779999911785126}],"concepts":[{"id":"https://openalex.org/C2778524551","wikidata":"https://www.wikidata.org/wiki/Q7227206","display_name":"Pomalidomide","level":4,"score":0.8478647470474243},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7726472616195679},{"id":"https://openalex.org/C2776063141","wikidata":"https://www.wikidata.org/wiki/Q425681","display_name":"Lenalidomide","level":3,"score":0.6453338265419006},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.569864809513092},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.549599289894104},{"id":"https://openalex.org/C2780401358","wikidata":"https://www.wikidata.org/wiki/Q422252","display_name":"Dexamethasone","level":2,"score":0.5079312920570374},{"id":"https://openalex.org/C2779609412","wikidata":"https://www.wikidata.org/wiki/Q203174","display_name":"Thalidomide","level":3,"score":0.505120575428009},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.48229411244392395},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.42518913745880127},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.4025292694568634},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.3714679181575775},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3458067774772644},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.27970337867736816},{"id":"https://openalex.org/C87355193","wikidata":"https://www.wikidata.org/wiki/Q411","display_name":"Astrobiology","level":1,"score":0.0},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v114.22.301.301","doi":"https://doi.org/10.1182/blood.v114.22.301.301","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v114.22.301.301","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2527546807","https://openalex.org/W2588865522","https://openalex.org/W1971305591","https://openalex.org/W2552807584","https://openalex.org/W2464924193","https://openalex.org/W2966795888","https://openalex.org/W282179204","https://openalex.org/W2979737561","https://openalex.org/W4206651001","https://openalex.org/W2136541422"],"abstract_inverted_index":{"Abstract":[0,1],"301":[2],"Background:":[3],"Pomalidomide":[4,768],"(POM)":[5],"is":[6,288,604,672,769,776],"an":[7,667,695,706,718,730,742,757,770,813,824],"IMiD\u00ae":[8],"derived":[9],"from":[10,257],"thalidomide":[11],"with":[12,17,41,95,116,198,265,293,335,370,376,441,489,517,552,567,602,606,628,638,643],"a":[13,99,103,133,673],"modified":[14,245],"chemical":[15],"structure":[16],"improved":[18,580],"potency":[19],"in":[20,28,39,78,114,219,233,348,600,615,647,685,777],"vitro":[21],"and":[22,25,89,127,167,222,237,244,250,275,283,326,388,533,560,619,635,671,753,772],"potential":[23],"efficacy":[24,90,284],"safety":[26,88,282,669],"benefits":[27],"vivo.":[29],"Two":[30],"phase":[31],"(Ph)":[32],"1b,":[33],"single-center,":[34],"ascending":[35],"dose,":[36],"open-label":[37,144],"studies":[38],"pts":[40,81,115,152,155,161,267,272,277,404,492,577,627],"relapsed/refractory":[42,117,158,629,781],"multiple":[43],"myeloma":[44],"(MM;":[45],"Schey":[46],"et":[47,51],"al,":[48,52],"2004,":[49],"Streetly":[50],"2008)":[53],"identified":[54],"maximum":[55],"tolerated":[56],"dose":[57,188,311,423,640],"(MTD)":[58],"as":[59,381],"2mg":[60],"QD":[61,166,180],"or":[62,94,213,227,435,511,599,609,700,711,723,735,747,762,818,829],"5mg":[63],"on":[64,98,181,397,549,563,694,705,717,729,741,756,812,823],"alternate":[65],"days":[66],"(28":[67],"of":[68,75,91,184,190,211,260,296,406,412,459,480,513,528,536,555,570,633,641,698,709,721,733,745,760,816,827],"each":[69,422],"28-day":[70,185],"cycle).":[71],"High":[72],"response":[73,212,445,460],"rates":[74],"POM":[76,92,136,149,177,191,315,355,372,442,481,550,564,597,642,665],"alone":[77,93,150,551,598],"heavily":[79,625],"pretreated":[80,626],"were":[82,196,239,309,328,391,394,419,544],"encouraging.":[83],"To":[84],"evaluate":[85],"the":[86,261,329],"MTD,":[87],"Dexamathasone":[96],"(dex)":[97],"21/28":[100],"day":[101],"schedule,":[102],"Ph":[104,134,142,175,220,234,258],"1/2,":[105],"multicenter,":[106],"randomized,":[107],"open-label,":[108],"3\u00d73":[109],"dose-escalation":[110],"study":[111,131,262,398],"was":[112,178,437,454,462,472,485,524,583,613],"initiated":[113],"MM":[118],"after":[119,206,321,581],"at":[120,203,421,500],"least":[121],"2":[122,143,403,450,587],"prior":[123,297],"regimens,":[124],"including":[125],"bortezomib":[126],"lenalidomide.":[128],"Methods:":[129],"The":[130,631,652],"has":[132,303,654,666],"1":[135,221,259,409,448,589],"MTD":[137,302,653],"(n=32)":[138],"portion,":[139],"followed":[140],"by":[141],"randomized":[145],"POM+":[146],"dex":[147,202,367,374,483,495,566,582,603],"vs":[148],"(192":[151],"planned).":[153],"Eligible":[154],"had":[156],"documented":[157],"MM.":[159,630,782],"All":[160],"received":[162],"low-dose":[163],"prophylactic":[164],"aspirin":[165],"monitored":[168],"for":[169,209,225,248,280,509,678,780],"venous":[170],"thromboembolic":[171],"events":[172,345,353],"(VTE).":[173],"In":[174,427,541,575],"1,":[176],"given":[179],"Days":[182],"1\u201321":[183],"cycle:":[186],"4":[187,207,310,486],"levels":[189],"(2,":[192],"3,":[193,506],"4,":[194],"5mg)":[195],"studied":[197],"option":[199,677],"to":[200,269,314,401,416,469,497,658],"add":[201],"40":[204],"mg/wk":[205],"cycles":[208,479,503],"lack":[210,512],"progressive":[214],"disease":[215],"(PD).":[216],"Pts":[217],"enrolled":[218,232,268],"discontinued":[223,273],"either":[224],"intolerance":[226],"PD":[228,510],"could":[229],"not":[230,304,399,655],"be":[231],"2.":[235],"Toxicities":[236],"responses":[238,579],"assessed":[240],"using":[241],"CTCAE":[242],"v3":[243],"European":[246],"Group":[247],"Blood":[249],"Marrow":[251],"Transplantation":[252],"(EBMT)":[253],"criteria.":[254],"Results:":[255],"Results":[256],"are":[263,278],"reported":[264],"32":[266],"date.":[270,659],"Fifteen":[271],"therapy":[274],"17":[276],"ongoing":[279],"both":[281],"analyses.":[285],"Mean":[286],"age":[287],"66.6":[289],"yrs":[290],"(range":[291,300,464,474,487,530,538,557,572],"38\u201384),":[292],"median":[294],"number":[295],"regimens":[298,499],"7":[299],"2\u201318).":[301],"yet":[305],"been":[306,656],"reached.":[307],"There":[308,393],"reductions":[312],"due":[313,415],"(5mg":[316],"[2-neutropenia,":[317],"1-rash];":[318],"3mg":[319],"[1-neutropenia])":[320],"108":[322],"completed":[323,478],"cycles.":[324],"Neutropenia":[325],"thrombocytopenia":[327],"most":[330],"common":[331],"grade":[332,648],"3/4":[333,649],"toxicities,":[334],"no":[336,644],"dose-dependent":[337,645],"increase":[338,646],"apparent":[339],"so":[340],"far:":[341],"12":[342],"serious":[343],"adverse":[344],"(SAEs)":[346],"occurred":[347],"10":[349],"pts;":[350],"drug":[351],"related":[352],"included":[354],"(VTE,":[356],"syncope,":[357],"3rd":[358],"degree":[359],"AV":[360],"block,":[361],"asthenia,":[362],"diarrhea,":[363],"neutropenia,":[364],"anemia,":[365],"rash);":[366],"(lung":[368],"infection":[369],"neutropenia);":[371],"+":[373,565,622],"(sepsis":[375],"pharyngeal":[377],"abscess).":[378],"AEs":[379],"such":[380],"somnolence":[382],"(1)":[383,385],"VTE":[384],"neuropathy":[386],"(2),":[387],"constipation":[389],"(4)":[390],"uncommon.":[392],"3":[395,522],"deaths":[396],"attributed":[400],"POM;":[402],"died":[405,411],"rapid":[407],"PD,":[408],"pt":[410],"gastrointestinal":[413],"perforation":[414],"amyloidosis.":[417],"Responses":[418],"seen":[420],"level":[424],"(Table":[425],"1).":[426],"20/21":[428],"(95%)":[429],"evaluable":[430,491],"pts,":[431],"clinical":[432,778],"activity":[433],"(SD":[434],"better)":[436],"reported.":[438],"During":[439,515],"treatment":[440,516],"alone,":[443],"overall":[444,484],"rate":[446],"(ORR;":[447],"CR,":[449],"PR,":[451,521,586],"5":[452],"MR)":[453,523],"38%":[455,607],"(8/21),":[456],"mean":[457,467,526,534,553,568],"duration":[458],"(DOR)":[461],"11.1":[463],"4\u201332)":[465,531],"wks,":[466,532,559],"time":[468],"progression":[470],"(TTP)":[471],"8.3":[473],"2\u201336)":[475],"wks.":[476,540,574],"Median":[477],"+/\u2212":[482],"1\u201312),":[488],"13/21":[490],"(62%)":[493],"having":[494],"added":[496,584],"their":[498],"various":[501],"different":[502],"(median":[504],"cycle":[505],"range":[507],"2\u20139)":[508],"response.":[514],"POM+dex,":[518],"ORR":[519],"(2":[520,585],"38%,":[525],"DOR":[527,554,569],"14.2":[529],"TTP":[535],"20":[537],"4\u201352)":[539],"addition,":[542],"there":[543],"9":[545],"stable":[546],"diseases":[547],"(SD)":[548],"7.1":[556],"4\u201316)":[558],"6":[561],"SD":[562,612],"10.7":[571],"8\u201316)":[573],"5/13":[576],"(38%),":[578],"MR,":[588],"SD).":[590],"Conclusions:":[591],"These":[592],"preliminary":[593],"results":[594],"indicate":[595,663],"that":[596,664,775],"combination":[601],"associated":[605],"MR":[608],"better,":[610],"while":[611],"achieved":[614],"43%":[616],"(POM":[617,621],"alone)":[618],"46%":[620],"dex),":[623],"amongst":[624],"incidence":[632],"SAEs":[634],"discontinuations":[636],"decreased":[637],"increased":[639],"hematological":[650],"toxicities.":[651],"reached":[657],"Overall,":[660],"these":[661],"data":[662],"acceptable":[668],"profile":[670],"clinically":[674],"active":[675],"therapeutic":[676],"advanced":[679],"refractory":[680],"MM,":[681],"warranting":[682],"further":[683],"investigation":[684],"this":[686],"patient":[687],"population.":[688],"Disclosures:":[689],"Richardson:":[690],"Gentium":[691],"Pharmaceuticals:":[692,715,739,787,794,799,849],"Membership":[693,704,716,728,740,755,811,822],"entity's":[696,707,719,731,743,758,814,825],"Board":[697,708,720,732,744,759,815,826],"Directors":[699,710,722,734,746,761,817,828],"advisory":[701,712,724,736,748,763,819,830],"committees;":[702,713,725,737,820],"BMS:":[703],"Keryx":[714],"Celgene":[726],"Corporation:":[727],"Millenium":[738,786,798,848],"committees,":[749],"Research":[750,791,808],"Funding;":[751,809],"Johnson":[752],"Johnson:":[754],"committees.":[764,831],"Off":[765],"Label":[766],"Use:":[767],"anti-proliferative":[771],"immunomodulatory":[773],"agent":[774],"development":[779],"Siegel:Celgene:":[783],"Speakers":[784,788,796,801,805,833,846,852,857],"Bureau;":[785,797,802,847,853],"Bureau.":[789,806,834,858],"Baz:Celgene:":[790],"Funding.":[792],"Munshi:Novartis":[793],"Consultancy,":[795,800,804,844,850,855],"Celgene:":[803],"Sullivan:Merck:":[807],"Amgen:":[810],"Merrion:":[821],"Doss:Celgene:":[832],"Larkins:Celgene:":[835],"Employment,":[836],"Equity":[837],"Ownership.":[838],"Jacques:Celgene:":[839],"Employment.":[840,842],"Donaldson:Celgene:":[841],"Anderson:Celgene:":[843],"Honoraria,":[845,851,856],"Novartis:":[854]},"counts_by_year":[{"year":2017,"cited_by_count":1},{"year":2015,"cited_by_count":2},{"year":2014,"cited_by_count":1},{"year":2013,"cited_by_count":10},{"year":2012,"cited_by_count":8}],"updated_date":"2026-10-16T09:59:22.235173","created_date":"2016-12-16T00:00:00"}